ALK and non-small cell lung carcinoma: Other ongoing Phase III clinical trial such as J-ALK study, aiming to explore the postoperative adjuvant therapy with crizotinib versus pemetrexed/cisplatin in ALK-positive patients with completely resected NSCLC (NCT02194738), it is estimated to complete in 2023.